The emerging role of lipidomics

Atherosclerosis

Volumn 221, Issue 1, 2012, Pages 38-40

  Stock, Jane ^a  

^a On behalf of the European Atherosclerosis Society   (Sweden)

Author keywords

Atherosclerotic plaque; Coronary disease; Dyslipidemia; Lipidomics; Stable plaque; Vulnerable plaque

Indexed keywords

ACETYL COENZYME A; CHOLESTEROL ESTER; FATTY ACID; FENOFIBRATE; GLYCEROLIPID; GLYCEROPHOSPHOLIPID; HIGH DENSITY LIPOPROTEIN; ICOSANOID; LIPID; LIPIDOME; LYSOPHOSPHATIDYLCHOLINE; PHOSPHATIDYLCHOLINE; SPHINGOLIPID; SPHINGOMYELIN; STEROL;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DRUG RESPONSE; DYSLIPIDEMIA; FATTY ACID METABOLISM; HUMAN; INTRACELLULAR SIGNALING; LIPID ANALYSIS; LIPID STORAGE; LIPIDOMICS; NOTE; PRIORITY JOURNAL; REVASCULARIZATION; RISK ASSESSMENT;

ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; HUMANS; HYPOLIPIDEMIC AGENTS; LIPID METABOLISM; METABOLOMICS; PLAQUE, ATHEROSCLEROTIC; PROGNOSIS; RUPTURE, SPONTANEOUS; TREATMENT OUTCOME;

EID: 84857029742     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.11.030     Document Type: Note

References (15)

1. Quehenberger O., Armando A.M., Brown A.H., et al. Lipidomics reveals a remarkable diversity of lipids in human plasma. J Lipid Res 2010, 51:3299-3305.
2. Dennis E.A., Deems R.A., Harkewicz R., et al. A mouse macrophage lipidome. J Biol Chem 2010, 285:39976-39985.
3. Camont L., Chapman M.J., Kontush A. Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol Med 2011, 17:594-603.
4. Kontush A., Therond P., Zerrad A., et al. Preferential sphingosine-1-phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: relevance to antiapoptotic and antioxidative activities. Arterioscler Thromb Vasc Biol 2007, 27:1843-1849.
5. de Souza J.A., Vindis C., Hansel B., et al. Metabolic syndrome features small, apolipoprotein A-I-poor, triglyceride-rich HDL3 particles with defective anti-apoptotic activity. Atherosclerosis 2008, 197:84-94.
6. Stegemann C., Drozdov I., Shalhoub J., et al. Comparative lipidomics profiling of human atherosclerotic plaques. Circ Cardiovasc Genet 2011, 4:232-242.
7. Ray K.K., Cannon C.P., McCabe C.H., et al. PROVE IT-TIMI 22 Investigators. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005, 46:1405-1410.
8. Meikle P.J., Wong G., Tsorotes D., et al. Plasma lipidomic analysis of stable and unstable coronary artery disease. Arterioscler Thromb Vasc Biol 2011, 31:2723-2732.
9. Ford D.A. Lipid oxidation by hypochlorous acid: chlorinated lipids in atherosclerosis and myocardial ischemia. Clin Lipidol 2010, 5:835-852.
10. White A.J., Duffy S.J., Walton A.S., et al. Matrix metalloproteinase-3 and coronary remodelling: implications for unstable coronary disease. Cardiovasc Res 2007, 75:813-820.
11. Keech A., Simes R.J., Barter P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849-1861.
12. Hiukka A., Leinonen E., Jauhiainen M., et al. Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus. Diabetologia 2007, 50:2067-2075.
13. Taskinen M.-R., Sullivan D.R., Ehnholm C., et al. Relationships of HDL cholesterol, apoA-I, and apoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate. Arterioscler Thromb Vasc Biol 2009, 29:950-955.
14. Yetukuri L., Huopaniemi I., Koivuniemi A., et al. High density lipoprotein structural changes and drug response in lipidomic profiles following the long-term fenofibrate therapy in the FIELD substudy. PLoS One 2011, 6:e23589.
15. Gorgas K., Teigler A., Komljenovic D., Just W.W. The ether lipid-deficient mouse: tracking down plasmalogen functions. Biochim Biophys Acta 2006, 1763:1511-1526.